BioCentury | Apr 5, 2019
Company News

EspeRare, Dermelix to develop in utero therapy for rare disease

...Dermelix partnered with the EspeRare Foundation to develop DMX-101 for X-linked hypohydrotic ectodermal dysplasia, a rare pediatric...
...the U.S. and PRIority MEdicines (PRIME) designation in the EU. Hongjiang Li, Staff Writer Ectodysplasin 1 (EDA) Dermelix Biotherapeutics DMX-101 EspeRare Foundation...
BioCentury | Apr 22, 2013
Company News

Merck KGaA musculoskeletal, pharmaceuticals news

...Merck's Merck Serono S.A. unit launched the not-for-profit EspeRare Foundation to reposition existing drugs to treat rare...
Items per page:
1 - 2 of 2
BioCentury | Apr 5, 2019
Company News

EspeRare, Dermelix to develop in utero therapy for rare disease

...Dermelix partnered with the EspeRare Foundation to develop DMX-101 for X-linked hypohydrotic ectodermal dysplasia, a rare pediatric...
...the U.S. and PRIority MEdicines (PRIME) designation in the EU. Hongjiang Li, Staff Writer Ectodysplasin 1 (EDA) Dermelix Biotherapeutics DMX-101 EspeRare Foundation...
BioCentury | Apr 22, 2013
Company News

Merck KGaA musculoskeletal, pharmaceuticals news

...Merck's Merck Serono S.A. unit launched the not-for-profit EspeRare Foundation to reposition existing drugs to treat rare...
Items per page:
1 - 2 of 2